<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03309202</url>
  </required_header>
  <id_info>
    <org_study_id>C1171006</org_study_id>
    <secondary_id>2017-003034-86</secondary_id>
    <nct_id>NCT03309202</nct_id>
  </id_info>
  <brief_title>Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment</brief_title>
  <official_title>A Phase 1, Non-randomized, Open-label, Single-dose, Parallel Cohort Study To Compare The Pharmacokinetics Of Pf-05221304 In Adult Subjects With Varying Degrees Of Hepatic Impairment Relative To Subjects Without Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatic impairment PK study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non randomized, open label, single dose, parallel cohort, multisite study to
      investigate the effect of varying degrees of hepatic impairment on the plasma
      pharmacokinetics (total and unbound) of PF-05221304 after a single oral dose administered in
      the fed state.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2017</start_date>
  <completion_date type="Anticipated">December 17, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 17, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for PF-05221304 (both total and unbound)</measure>
    <time_frame>0, 1, 2, 3, 4, 5, 8, 10, 16, 24, 36, 48, 72, 96, 120, and 144 hours post dose</time_frame>
    <description>Maximum Observed Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0- infinity)] for PF-05221304 (as permitted for both total and unbound)</measure>
    <time_frame>0, 1, 2, 3, 4, 5, 8, 10, 16, 24, 36, 48, 72, 96, 120, and 144 hours post dose</time_frame>
    <description>AUC (0-infinity)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-infinity). It is obtained from AUC (0-t) plus AUC (t-infinity).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fraction of Unbound Drug</measure>
    <time_frame>0, 1, 2, 3, 4, 5, 8, 10, 16, 24, 36, 48, 72, 96, 120, and 144 hours post dose</time_frame>
    <description>Fraction of unbound drug (fu) is defined as the ratio of unbound drug concentration to the total drug concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects experiencing an Adverse Event</measure>
    <time_frame>Screening up to 28 days after last dose of study medication</time_frame>
    <description>Assessment by adverse event monitoring, 12 lead ECGs, telemetry, vital signs and clinical safety laboratory measurements.
Treatment-related AE was any untoward medical occurrence attributed to study drug in a subject who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to Drug was assessed by the investigator (Yes/No). Subjects with multiple occurrences of an AE within a category were counted once within the category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Concentration for PF-05221304 (as permitted)</measure>
    <time_frame>0, 1, 2, 3, 4, 5, 8, 10, 16, 24, 36, 48, 72, 96, 120, and 144 hours post dose</time_frame>
    <description>Time to Reach Maximum Observed Plasma Concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-05221304 (as permitted for both total and unbound)</measure>
    <time_frame>0, 1, 2, 3, 4, 5, 8, 10, 16, 24, 36, 48, 72, 96, 120, and 144 hours post dose</time_frame>
    <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Body Clearance (CL/F) for PF-05221304 (as permitted for both total and unbound)</measure>
    <time_frame>0, 1, 2, 3, 4, 5, 8, 10, 16, 24, 36, 48, 72, 96, 120, and 144 hours post dose</time_frame>
    <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after apparent total body clearance is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) for PF-05221304 (as permitted for both total and unbound)</measure>
    <time_frame>0, 1, 2, 3, 4, 5, 8, 10, 16, 24, 36, 48, 72, 96, 120, and 144 hours post dose</time_frame>
    <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) for PF-05221304 (as permitted)</measure>
    <time_frame>0, 1, 2, 3, 4, 5, 8, 10, 16, 24, 36, 48, 72, 96, 120, and 144 hours post dose</time_frame>
    <description>Plasma Decay Half-Life (t1/2)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Cohort 1_Without impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, 25 mg dose of PF-05221304</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2_Mild impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, 25 mg dose of PF-05221304</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3_Moderate impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, 25 mg dose of PF-05221304</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4_Severe impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, 25 mg dose of PF-05221304</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05221304</intervention_name>
    <description>25 mg dose</description>
    <arm_group_label>Cohort 1_Without impairment</arm_group_label>
    <arm_group_label>Cohort 2_Mild impairment</arm_group_label>
    <arm_group_label>Cohort 3_Moderate impairment</arm_group_label>
    <arm_group_label>Cohort 4_Severe impairment</arm_group_label>
    <other_name>experimental drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Exclusion Criteria:

        All subjects -

          -  Adults &lt;18 years of age and &gt;70 years of age

          -  BMI &lt; 17.5 and &gt; 35.4 kg/m2

          -  HIV positive

          -  Conditions that affect drug absorption

          -  Positive breath alcohol test

        Healthy/ those without hepatic impairment -

          -  Known or suspected hepatic impairment

          -  Evidence of Hepatitis B or C

          -  On any chronic medications

        Those with varying degrees of hepatic impairment -

          -  Not meeting Classification A, B, or C of hepatic impairment based on Child-Pugh
             Classification

          -  Evidence of Hepatic carcinoma or hepatorenal syndrome or limited predicted life
             expectancy

          -  Recent GI bleed

          -  Moderate or severe renal impairment

          -  Hepatic encephalopathy Grade 3 or higher
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Clinical Research Unit</name>
      <address>
        <city>Brussels</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pharmaceutical Research Associates CZ, s.r.o.</name>
      <address>
        <city>Praha 7</city>
        <zip>170 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Bulovce</name>
      <address>
        <city>Praha 8</city>
        <zip>180 81</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Summit Clinical Research s.r.o.</name>
      <address>
        <city>Bratislava</city>
        <zip>83101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univerzitn√° Nemocnica Bratislava</name>
      <address>
        <city>Bratislava</city>
        <zip>83305</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Slovakia</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C1171006&amp;StudyName=A+Phase+1%2C+Non-randomized%2C+Open-label%2C+Single-dose%2C+Parallel+Cohort+Study+To+Compare+The+Pharmacokinetics+Of+Pf-05221304+Between+Healthy+Adult+Subjects+And+Those+With+Varying+Degrees+Of+Hepatic+Impairment</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C1171006&amp;StudyName=A+Phase+1%2C+Non-randomized%2C+Open-label%2C+Single-dose%2C+Parallel+Cohort+Study+To+Compare+The+Pharmacokinetics+Of+Pf-05221304+In+Adult+Subjects+With+Varying+Degrees+Of+Hepatic+Impairment+Relative+To+Subjects+Without+Hepatic+Impairment</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>October 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2017</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

